Read More

AVROBIO Announced Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy Annual Meeting; Said Data Support Plans to Initiate Clinical Trial in 2023

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease.

AVRO